Sipuleucel-T, an autologous cancer vaccine prepared from peripheral blood mononuclear cells (PBMCs) that have been activated and expanded ex vivo with a recombinant fusion protein consisting of prostatic acid phosphatase fused to granulocyte-macrophage colony-stimulating factor (GM-CSF), has been licensed for treatment of castration-resistant prostate cancer [6, 7]. The gene discussed is CSF2; the disease is cancer.